The prevalence of long-term oral anticoagulation therapy in a cardiology center in Bucharest, Romania.

Clujul medical (1957) Pub Date : 2018-01-01 Epub Date: 2018-01-15 DOI:10.15386/cjmed-837
Adelina-Mihaela Sorescu, Tudor Enache, Suzana Guberna
{"title":"The prevalence of long-term oral anticoagulation therapy in a cardiology center in Bucharest, Romania.","authors":"Adelina-Mihaela Sorescu,&nbsp;Tudor Enache,&nbsp;Suzana Guberna","doi":"10.15386/cjmed-837","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Few studies discuss the prevalence of oral anticoagulation therapy (OAT) in clinical practice, despite their increasing use worldwide. In America, studies established that 20% to 80% of the patients with indication benefit from OAT. In Romania, there is no data regarding the utilization of oral anticoagulants. Thus, this study aims to determine the trends of OAT.</p><p><strong>Methods: </strong>We designed a cross-sectional study of the patients admitted to the Cardiology Department of the \"Bagdasar-Arseni\" Clinical Emergency Hospital, Bucharest, from the 1st of November 2016 until the 31st of January 2017. We considered OAT indications to be: atrial fibrillation/flutter (AF), pulmonary embolisms (PE), deep vein thrombosis (DVT), intramural or intracavitary thrombi and left ventricle aneurysms. Statistical analysis was performed with EpiInfo.</p><p><strong>Results: </strong>There were 783 patients admitted, 253 of these having an OAT indication (mean age 73.25 years, 53.75% female). Only 162 patients (64.03%) received it, either Vitamin K Antagonists (VKA) (78 patients, 48.14%), or Novel Oral Anticoagulants (NOAC) (84 patients, 51.85%). Reasons for not indicating such therapy included the hemorrhage risk (43.27%), the lack of adherence to the treatment (18.56%), the impossibility of INR monitoring (21.84%), the economic status (10.21%) and others (6.12%). 221 patients had AF (87.35%), 141 (63.8%) receiving OAT, VKA (67 patients, 47.51%), or NOAC (74 patients, 52.48%). 17 patients (6.71%) had a PE and/or DVT. 15 (88.23%) received OAT, AVK (11 patients, 73.33%), or NOAC (4 patients, 26.67%). 15 patients (5.92%) had other OAT indications (excepting AF or PE/DVT), 11 receiving OAT (73.33%), AVK (8 patients, 72.72%), or NOAC (3 patients, 27.27%).</p><p><strong>Conclusions: </strong>Our study determined that 64.03% of those with indication received OAT. Similar data is reported in the USA, suggesting an underuse of anticoagulants. The risk of hemorrhage, lack of adherence, the impossibility of INR monitoring or the economic status were some of the reasons for not recommending OAT.</p>","PeriodicalId":91233,"journal":{"name":"Clujul medical (1957)","volume":"91 1","pages":"37-41"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.15386/cjmed-837","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clujul medical (1957)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15386/cjmed-837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/15 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background and aims: Few studies discuss the prevalence of oral anticoagulation therapy (OAT) in clinical practice, despite their increasing use worldwide. In America, studies established that 20% to 80% of the patients with indication benefit from OAT. In Romania, there is no data regarding the utilization of oral anticoagulants. Thus, this study aims to determine the trends of OAT.

Methods: We designed a cross-sectional study of the patients admitted to the Cardiology Department of the "Bagdasar-Arseni" Clinical Emergency Hospital, Bucharest, from the 1st of November 2016 until the 31st of January 2017. We considered OAT indications to be: atrial fibrillation/flutter (AF), pulmonary embolisms (PE), deep vein thrombosis (DVT), intramural or intracavitary thrombi and left ventricle aneurysms. Statistical analysis was performed with EpiInfo.

Results: There were 783 patients admitted, 253 of these having an OAT indication (mean age 73.25 years, 53.75% female). Only 162 patients (64.03%) received it, either Vitamin K Antagonists (VKA) (78 patients, 48.14%), or Novel Oral Anticoagulants (NOAC) (84 patients, 51.85%). Reasons for not indicating such therapy included the hemorrhage risk (43.27%), the lack of adherence to the treatment (18.56%), the impossibility of INR monitoring (21.84%), the economic status (10.21%) and others (6.12%). 221 patients had AF (87.35%), 141 (63.8%) receiving OAT, VKA (67 patients, 47.51%), or NOAC (74 patients, 52.48%). 17 patients (6.71%) had a PE and/or DVT. 15 (88.23%) received OAT, AVK (11 patients, 73.33%), or NOAC (4 patients, 26.67%). 15 patients (5.92%) had other OAT indications (excepting AF or PE/DVT), 11 receiving OAT (73.33%), AVK (8 patients, 72.72%), or NOAC (3 patients, 27.27%).

Conclusions: Our study determined that 64.03% of those with indication received OAT. Similar data is reported in the USA, suggesting an underuse of anticoagulants. The risk of hemorrhage, lack of adherence, the impossibility of INR monitoring or the economic status were some of the reasons for not recommending OAT.

Abstract Image

Abstract Image

Abstract Image

罗马尼亚布加勒斯特某心脏病中心长期口服抗凝治疗的流行情况。
背景和目的:很少有研究讨论口服抗凝治疗(OAT)在临床实践中的流行情况,尽管它们在世界范围内的使用越来越多。在美国,研究证实20% - 80%有适应症的患者从OAT中获益。在罗马尼亚,没有关于口服抗凝剂使用的数据。因此,本研究旨在确定OAT的趋势。方法:我们设计了一项横断面研究,研究对象是2016年11月1日至2017年1月31日在布加勒斯特“Bagdasar-Arseni”临床急诊医院心内科住院的患者。我们认为OAT的适应症是:心房颤动/扑动(AF)、肺栓塞(PE)、深静脉血栓(DVT)、壁内或腔内血栓和左心室动脉瘤。使用EpiInfo进行统计分析。结果:共收治783例患者,其中有OAT指征者253例,平均年龄73.25岁,女性53.75%。只有162例(64.03%)患者接受了维生素K拮抗剂(VKA)(78例,48.14%)或新型口服抗凝剂(NOAC)(84例,51.85%)。不建议进行此类治疗的原因包括出血风险(43.27%)、缺乏治疗依从性(18.56%)、无法进行INR监测(21.84%)、经济状况(10.21%)和其他(6.12%)。221例AF患者(87.35%),141例(63.8%)接受OAT、VKA(67例,47.51%)或NOAC(74例,52.48%)。17例(6.71%)有PE和/或DVT。接受OAT治疗15例(88.23%),AVK治疗11例(73.33%),NOAC治疗4例(26.67%)。15例患者(5.92%)有其他OAT适应症(AF或PE/DVT除外),11例患者接受OAT (73.33%), AVK(8例,72.72%)或NOAC(3例,27.27%)。结论:我们的研究确定64.03%的患者接受了OAT治疗。类似的数据在美国也有报道,表明抗凝剂的使用不足。出血风险、缺乏依从性、无法监测INR或经济状况是不推荐OAT的一些原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信